Terns Pharmaceuticals Showcases Promising Phase 1 Data at ASH Annual Meeting

Terns Pharmaceuticals shares are trading higher after the company announced positive Phase 1 clinical data for TERN-701, showcasing its potential best-in-disease profile for relapsed/refractory chronic myeloid leukemia at the ASH Annual Meeting.